Compare UiPath Inc (PATH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? UiPath Inc trades at $13.59 (market cap $7.26B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.5× UiPath Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| PATH | VRTX | |
|---|---|---|
Market Cap | $7.26B | $134.06B |
Sector | Technology | Health |
52-Week High | $19.29 | $557.96 |
52-Week Low | $9.38 | $376.62 |
Enterprise Value | $6.05B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $14.01, down 7.77% amid mixed signals. The stock is near its consensus price target low of $14.00. Revenue growth is improving, with 2025 revenue at $1.43 billion and a projected net profit margin of 21.03% for 2026. Technical indicators show a bearish near-term trend with RSI at oversold levels, while recent news highlights volatility following Q2 earnings.
The outlook is cautious; PATH shows fundamental improvement but faces execution risks and competitive pressure. Analyst consensus is predominantly Hold (70.84%), with a $17.38 price target suggesting modest upside. Key risks include slowing growth guidance and macroeconomic headwinds impacting software demand.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
